GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (SSE:4502) » Definitions » EV-to-EBITDA

Takeda Pharmaceutical Co (SSE:4502) EV-to-EBITDA : 9.94 (As of Apr. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Takeda Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Takeda Pharmaceutical Co's enterprise value is 円10,762,047 Mil. Takeda Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円1,082,815 Mil. Therefore, Takeda Pharmaceutical Co's EV-to-EBITDA for today is 9.94.

The historical rank and industry rank for Takeda Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

SSE:4502' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.93   Med: 11.5   Max: 59.15
Current: 9.94

During the past 13 years, the highest EV-to-EBITDA of Takeda Pharmaceutical Co was 59.15. The lowest was 6.93. And the median was 11.50.

SSE:4502's EV-to-EBITDA is ranked better than
65.54% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs SSE:4502: 9.94

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Takeda Pharmaceutical Co's stock price is 円4300.00. Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円112.610. Therefore, Takeda Pharmaceutical Co's PE Ratio for today is 38.18.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Takeda Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Takeda Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co EV-to-EBITDA Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.48 14.28 9.34 8.85 9.16

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.08 9.16 9.39 10.27 9.89

Competitive Comparison of Takeda Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's EV-to-EBITDA falls into.



Takeda Pharmaceutical Co EV-to-EBITDA Calculation

Takeda Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=10762046.594/1082815
=9.94

Takeda Pharmaceutical Co's current Enterprise Value is 円10,762,047 Mil.
Takeda Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,082,815 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (SSE:4502) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Takeda Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4300.00/112.610
=38.18

Takeda Pharmaceutical Co's share price for today is 円4300.00.
Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円112.610.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Takeda Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (SSE:4502) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (SSE:4502) Headlines

No Headlines